-
1
-
-
0025615213
-
Lung cancer with a single brain metastasis: therapeutic options
-
Rizzi A, Tondini M, Rocco G, Rossi G, Robustellini M, Radaelli F, Della Pona C. Lung cancer with a single brain metastasis: therapeutic options. Tumori. 1990; 76:579-581.
-
(1990)
Tumori
, vol.76
, pp. 579-581
-
-
Rizzi, A.1
Tondini, M.2
Rocco, G.3
Rossi, G.4
Robustellini, M.5
Radaelli, F.6
Della Pona, C.7
-
2
-
-
2142813718
-
Temporal and gender-related trends in brain metastases from lung and breast cancer
-
Yawn BP, Wollan PC, Schroeder C, Gazzuola L, Mehta M. Temporal and gender-related trends in brain metastases from lung and breast cancer. Minn Med. 2003; 86:32-37.
-
(2003)
Minn Med
, vol.86
, pp. 32-37
-
-
Yawn, B.P.1
Wollan, P.C.2
Schroeder, C.3
Gazzuola, L.4
Mehta, M.5
-
3
-
-
0032959628
-
Surgical strategies for metastatic lung cancer
-
Olak J. Surgical strategies for metastatic lung cancer. Surg Oncol Clin N Am. 1999; 8:245-257.
-
(1999)
Surg Oncol Clin N Am
, vol.8
, pp. 245-257
-
-
Olak, J.1
-
4
-
-
84857627477
-
Treatment of brain metastases: chemotherapy
-
Grimm SA. Treatment of brain metastases: chemotherapy. Curr Oncol Rep. 2012; 14:85-90.
-
(2012)
Curr Oncol Rep
, vol.14
, pp. 85-90
-
-
Grimm, S.A.1
-
5
-
-
0036161382
-
The seed and soil hypothesis: vascularisation and brain metastases
-
Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol. 2002; 3:53-57.
-
(2002)
Lancet Oncol
, vol.3
, pp. 53-57
-
-
Fidler, I.J.1
Yano, S.2
Zhang, R.D.3
Fujimaki, T.4
Bucana, C.D.5
-
6
-
-
0025615466
-
Influence of radiation on the blood-brain barrier and optimum time of chemotherapy
-
Qin DX, Zheng R, Tang J, Li JX, Hu YH. Influence of radiation on the blood-brain barrier and optimum time of chemotherapy. Int J Radiat Oncol Biol Phys. 1990; 19:1507-1510.
-
(1990)
Int J Radiat Oncol Biol Phys
, vol.19
, pp. 1507-1510
-
-
Qin, D.X.1
Zheng, R.2
Tang, J.3
Li, J.X.4
Hu, Y.H.5
-
7
-
-
22044445517
-
Erlotinib in previously treated non-small-cell lung cancer
-
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353:123-132.
-
(2005)
N Engl J Med
, vol.353
, pp. 123-132
-
-
Shepherd, F.A.1
Rodrigues Pereira, J.2
Ciuleanu, T.3
Tan, E.H.4
Hirsh, V.5
Thongprasert, S.6
Campos, D.7
Maoleekoonpiroj, S.8
Smylie, M.9
Martins, R.10
van Kooten, M.11
Dediu, M.12
Findlay, B.13
Tu, D.14
Johnston, D.15
Bezjak, A.16
-
8
-
-
27544503230
-
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
-
Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Lancet. 2005; 366:1527-1537.
-
(2005)
Lancet
, vol.366
, pp. 1527-1537
-
-
Thatcher, N.1
Chang, A.2
Parikh, P.3
Rodrigues Pereira, J.4
Ciuleanu, T.5
von Pawel, J.6
Thongprasert, S.7
Tan, E.H.8
Pemberton, K.9
Archer, V.10
Carroll, K.11
-
9
-
-
56249109644
-
Gefitinib versus docetaxel in previously treated non-smallcell lung cancer (INTEREST): a randomised phase III trial
-
Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, et al. Gefitinib versus docetaxel in previously treated non-smallcell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008; 372:1809-1818.
-
(2008)
Lancet
, vol.372
, pp. 1809-1818
-
-
Kim, E.S.1
Hirsh, V.2
Mok, T.3
Socinski, M.A.4
Gervais, R.5
Wu, Y.L.6
Li, L.Y.7
Watkins, C.L.8
Sellers, M.V.9
Lowe, E.S.10
Sun, Y.11
Liao, M.L.12
Osterlind, K.13
Reck, M.14
Armour, A.A.15
Shepherd, F.A.16
-
10
-
-
69949162760
-
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
-
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361:947-957.
-
(2009)
N Engl J Med
, vol.361
, pp. 947-957
-
-
Mok, T.S.1
Wu, Y.L.2
Thongprasert, S.3
Yang, C.H.4
Chu, D.T.5
Saijo, N.6
Sunpaweravong, P.7
Han, B.8
Margono, B.9
Ichinose, Y.10
Nishiwaki, Y.11
Ohe, Y.12
Yang, J.J.13
Chewaskulyong, B.14
Jiang, H.15
Duffield, E.L.16
-
11
-
-
0036848833
-
Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa)
-
Heimberger AB, Learn CA, Archer GE, McLendon RE, Chewning TA, Tuck FL, Pracyk JB, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res. 2002; 8:3496-3502.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 3496-3502
-
-
Heimberger, A.B.1
Learn, C.A.2
Archer, G.E.3
McLendon, R.E.4
Chewning, T.A.5
Tuck, F.L.6
Pracyk, J.B.7
Friedman, A.H.8
Friedman, H.S.9
Bigner, D.D.10
Sampson, J.H.11
-
12
-
-
34548049302
-
Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain
-
Wu C, Li YL, Wang ZM, Li Z, Zhang TX, Wei Z. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer. 2007; 57:359-364.
-
(2007)
Lung Cancer
, vol.57
, pp. 359-364
-
-
Wu, C.1
Li, Y.L.2
Wang, Z.M.3
Li, Z.4
Zhang, T.X.5
Wei, Z.6
-
13
-
-
4944226682
-
Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer
-
Hotta K, Kiura K, Ueoka H, Tabata M, Fujiwara K, Kozuki T, Okada T, Hisamoto A, Tanimoto M. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer. 2004; 46:255-261.
-
(2004)
Lung Cancer
, vol.46
, pp. 255-261
-
-
Hotta, K.1
Kiura, K.2
Ueoka, H.3
Tabata, M.4
Fujiwara, K.5
Kozuki, T.6
Okada, T.7
Hisamoto, A.8
Tanimoto, M.9
-
14
-
-
7444234824
-
Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases
-
Namba Y, Kijima T, Yokota S, Niinaka M, Kawamura S, Iwasaki T, Takeda Y, Kimura H, Okada T, Yamaguchi T, Nakagawa M, Okumura Y, Maeda H, Ito M. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer. 2004; 6:123-128.
-
(2004)
Clin Lung Cancer
, vol.6
, pp. 123-128
-
-
Namba, Y.1
Kijima, T.2
Yokota, S.3
Niinaka, M.4
Kawamura, S.5
Iwasaki, T.6
Takeda, Y.7
Kimura, H.8
Okada, T.9
Yamaguchi, T.10
Nakagawa, M.11
Okumura, Y.12
Maeda, H.13
Ito, M.14
-
15
-
-
1242306284
-
Effect of gefitinib (ZD1839) on metastatic brain tumour
-
Takahashi H, Ohrui T, Ebihara S, Yamada M, Sasaki H. Effect of gefitinib (ZD1839) on metastatic brain tumour. Lung Cancer. 2004; 43:371-372.
-
(2004)
Lung Cancer
, vol.43
, pp. 371-372
-
-
Takahashi, H.1
Ohrui, T.2
Ebihara, S.3
Yamada, M.4
Sasaki, H.5
-
16
-
-
33744481276
-
EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib
-
Shimato S, Mitsudomi T, Kosaka T, Yatabe Y, Wakabayashi T, Mizuno M, Nakahara N, Hatano H, Natsume A, Ishii D, Yoshida J. EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. Neuro Oncol. 2006; 8:137-144.
-
(2006)
Neuro Oncol
, vol.8
, pp. 137-144
-
-
Shimato, S.1
Mitsudomi, T.2
Kosaka, T.3
Yatabe, Y.4
Wakabayashi, T.5
Mizuno, M.6
Nakahara, N.7
Hatano, H.8
Natsume, A.9
Ishii, D.10
Yoshida, J.11
-
17
-
-
4143110253
-
Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial
-
Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crino L, Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol. 2004; 15:1042-1047.
-
(2004)
Ann Oncol
, vol.15
, pp. 1042-1047
-
-
Ceresoli, G.L.1
Cappuzzo, F.2
Gregorc, V.3
Bartolini, S.4
Crino, L.5
Villa, E.6
-
18
-
-
84865197331
-
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation
-
Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, Lee JS. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer. 2012; 77:556-560.
-
(2012)
Lung Cancer
, vol.77
, pp. 556-560
-
-
Park, S.J.1
Kim, H.T.2
Lee, D.H.3
Kim, K.P.4
Kim, S.W.5
Suh, C.6
Lee, J.S.7
-
19
-
-
84875720245
-
Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non-Small-Cell Lung Cancer
-
Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, Brown P, Sulman E, Heymach JV, et al. Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non-Small-Cell Lung Cancer. J Clin Oncol. 2013: 31:895-902.
-
(2013)
J Clin Oncol
, vol.31
, pp. 895-902
-
-
Welsh, J.W.1
Komaki, R.2
Amini, A.3
Munsell, M.F.4
Unger, W.5
Allen, P.K.6
Chang, J.Y.7
Wefel, J.S.8
McGovern, S.L.9
Garland, L.L.10
Chen, S.S.11
Holt, J.12
Liao, Z.13
Brown, P.14
Sulman, E.15
Heymach, J.V.16
-
20
-
-
67449122414
-
Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population
-
Ma SL, Xu YP, Deng QH, Yu XM. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer. 2009; 65:198-203.
-
(2009)
Lung Cancer
, vol.65
, pp. 198-203
-
-
Ma, S.L.1
Xu, Y.P.2
Deng, Q.H.3
Yu, X.M.4
-
21
-
-
0036632353
-
Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review)
-
van Vulpen M, Kal HB, Taphoorn MJ, El-Sharouni SY. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncol Rep. 2002; 9:683-688.
-
(2002)
Oncol Rep
, vol.9
, pp. 683-688
-
-
van Vulpen, M.1
Kal, H.B.2
Taphoorn, M.J.3
El-Sharouni, S.Y.4
-
22
-
-
33749046899
-
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib
-
Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, Janne PA, Johnson BE. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006; 24:4517-4520.
-
(2006)
J Clin Oncol
, vol.24
, pp. 4517-4520
-
-
Jackman, D.M.1
Holmes, A.J.2
Lindeman, N.3
Wen, P.Y.4
Kesari, S.5
Borras, A.M.6
Bailey, C.7
de Jong, F.8
Janne, P.A.9
Johnson, B.E.10
-
23
-
-
44449131799
-
Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene
-
Fukuhara T, Saijo Y, Sakakibara T, Inoue A, Morikawa N, Kanamori M, Nakashima I, Nukiwa T. Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene. Tohoku J Exp Med. 2008; 214:359-363.
-
(2008)
Tohoku J Exp Med
, vol.214
, pp. 359-363
-
-
Fukuhara, T.1
Saijo, Y.2
Sakakibara, T.3
Inoue, A.4
Morikawa, N.5
Kanamori, M.6
Nakashima, I.7
Nukiwa, T.8
-
24
-
-
84875235273
-
Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma
-
Zhao J, Chen M, Zhong W, Zhang L, Li L, Xiao Y, Nie L, Hu P, Wang M. Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clin Lung Cancer. 2013; 14:188-193.
-
(2013)
Clin Lung Cancer
, vol.14
, pp. 188-193
-
-
Zhao, J.1
Chen, M.2
Zhong, W.3
Zhang, L.4
Li, L.5
Xiao, Y.6
Nie, L.7
Hu, P.8
Wang, M.9
-
25
-
-
84866364723
-
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
-
Togashi Y, Masago K, Masuda S, Mizuno T, Fukudo M, Ikemi Y, Sakamori Y, Nagai H, Kim YH, Katsura T, Mishima M. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2012; 70:399-405.
-
(2012)
Cancer Chemother Pharmacol
, vol.70
, pp. 399-405
-
-
Togashi, Y.1
Masago, K.2
Masuda, S.3
Mizuno, T.4
Fukudo, M.5
Ikemi, Y.6
Sakamori, Y.7
Nagai, H.8
Kim, Y.H.9
Katsura, T.10
Mishima, M.11
-
26
-
-
77954427100
-
Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer
-
Togashi Y, Masago K, Fukudo M, Terada T, Fujita S, Irisa K, Sakamori Y, Kim YH, Mio T, Inui K, Mishima M. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol. 2010; 5:950-955.
-
(2010)
J Thorac Oncol
, vol.5
, pp. 950-955
-
-
Togashi, Y.1
Masago, K.2
Fukudo, M.3
Terada, T.4
Fujita, S.5
Irisa, K.6
Sakamori, Y.7
Kim, Y.H.8
Mio, T.9
Inui, K.10
Mishima, M.11
-
27
-
-
79959614287
-
Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy
-
Masuda T, Hattori N, Hamada A, Iwamoto H, Ohshimo S, Kanehara M, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Kohno N. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother Pharmacol. 2011; 67:1465-1469.
-
(2011)
Cancer Chemother Pharmacol
, vol.67
, pp. 1465-1469
-
-
Masuda, T.1
Hattori, N.2
Hamada, A.3
Iwamoto, H.4
Ohshimo, S.5
Kanehara, M.6
Ishikawa, N.7
Fujitaka, K.8
Haruta, Y.9
Murai, H.10
Kohno, N.11
-
28
-
-
33947385893
-
Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420
-
Broniscer A, Panetta JC, O'Shaughnessy M, Fraga C, Bai F, Krasin MJ, Gajjar A, Stewart CF. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res. 2007; 13:1511-1515.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 1511-1515
-
-
Broniscer, A.1
Panetta, J.C.2
O'Shaughnessy, M.3
Fraga, C.4
Bai, F.5
Krasin, M.J.6
Gajjar, A.7
Stewart, C.F.8
-
29
-
-
84916879495
-
The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from nonsmall-cell lung cancer
-
Deng Y, Feng W, Wu J, Chen Z, Tang Y, Zhang H, Liang J, Xian H, Zhang S. The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from nonsmall-cell lung cancer. Mol Clin Oncol. 2014; 2:116-120.
-
(2014)
Mol Clin Oncol
, vol.2
, pp. 116-120
-
-
Deng, Y.1
Feng, W.2
Wu, J.3
Chen, Z.4
Tang, Y.5
Zhang, H.6
Liang, J.7
Xian, H.8
Zhang, S.9
-
30
-
-
0032246317
-
Radiation-induced blood-brain barrier changes: pathophysiological mechanisms and clinical implications
-
d'Avella D, Cicciarello R, Angileri FF, Lucerna S, La Torre D, Tomasello F. Radiation-induced blood-brain barrier changes: pathophysiological mechanisms and clinical implications. Acta Neurochir Suppl. 1998; 71:282-284.
-
(1998)
Acta Neurochir Suppl
, vol.71
, pp. 282-284
-
-
d'Avella, D.1
Cicciarello, R.2
Angileri, F.F.3
Lucerna, S.4
La Torre, D.5
Tomasello, F.6
-
31
-
-
0141450250
-
Influence of radiation on the blood-brain barrier and optimum time of chemotherapy
-
Qin D, Zheng R, Ma J, Xiao J, Tang Z. Influence of radiation on the blood-brain barrier and optimum time of chemotherapy. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1999; 21:307-310.
-
(1999)
Zhongguo Yi Xue Ke Xue Yuan Xue Bao
, vol.21
, pp. 307-310
-
-
Qin, D.1
Zheng, R.2
Ma, J.3
Xiao, J.4
Tang, Z.5
-
32
-
-
0026501854
-
Quantitative study of blood-brain barrier permeability changes after experimental whole-brain radiation
-
d'Avella D, Cicciarello R, Albiero F, Mesiti M, Gagliardi ME, Russi E, d'Aquino A, Tomasello F, d'Aquino S. Quantitative study of blood-brain barrier permeability changes after experimental whole-brain radiation. Neurosurgery. 1992; 30:30-34.
-
(1992)
Neurosurgery
, vol.30
, pp. 30-34
-
-
d'Avella, D.1
Cicciarello, R.2
Albiero, F.3
Mesiti, M.4
Gagliardi, M.E.5
Russi, E.6
d'Aquino, A.7
Tomasello, F.8
d'Aquino, S.9
-
33
-
-
0031005544
-
Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agents
-
Qin D, Ma J, Xiao J, Tang Z. Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agents. Am J Clin Oncol. 1997; 20:263-265.
-
(1997)
Am J Clin Oncol
, vol.20
, pp. 263-265
-
-
Qin, D.1
Ma, J.2
Xiao, J.3
Tang, Z.4
-
34
-
-
80054687830
-
Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid
-
Khatri A, Gaber MW, Brundage RC, Naimark MD, Hanna SK, Stewart CF, Kirstein MN. Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid. Cancer Chemother Pharmacol. 2011; 68:721-731.
-
(2011)
Cancer Chemother Pharmacol
, vol.68
, pp. 721-731
-
-
Khatri, A.1
Gaber, M.W.2
Brundage, R.C.3
Naimark, M.D.4
Hanna, S.K.5
Stewart, C.F.6
Kirstein, M.N.7
-
35
-
-
0037142314
-
A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials
-
Jones HK, Stafford LE, Swaisland HC, Payne R. A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials. J Pharm Biomed Anal. 2002; 29:221-228.
-
(2002)
J Pharm Biomed Anal
, vol.29
, pp. 221-228
-
-
Jones, H.K.1
Stafford, L.E.2
Swaisland, H.C.3
Payne, R.4
-
36
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92:205-216.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
Verweij, J.7
Van Glabbeke, M.8
van Oosterom, A.T.9
Christian, M.C.10
Gwyther, S.G.11
-
37
-
-
23844491524
-
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations
-
Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Janne PA. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer I. 2005; 97:1185-1194.
-
(2005)
J Natl Cancer I
, vol.97
, pp. 1185-1194
-
-
Mukohara, T.1
Engelman, J.A.2
Hanna, N.H.3
Yeap, B.Y.4
Kobayashi, S.5
Lindeman, N.6
Halmos, B.7
Pearlberg, J.8
Tsuchihashi, Z.9
Cantley, L.C.10
Tenen, D.G.11
Johnson, B.E.12
Janne, P.A.13
-
38
-
-
67049096054
-
Radiation-induced astrogliosis and bloodbrain barrier damage can be abrogated using anti-TNF treatment
-
Wilson CM, Gaber MW, Sabek OM, Zawaski JA, Merchant TE. Radiation-induced astrogliosis and bloodbrain barrier damage can be abrogated using anti-TNF treatment. Int J Radiat Oncol Biol Phys. 2009; 74:934-941.
-
(2009)
Int J Radiat Oncol Biol Phys
, vol.74
, pp. 934-941
-
-
Wilson, C.M.1
Gaber, M.W.2
Sabek, O.M.3
Zawaski, J.A.4
Merchant, T.E.5
-
39
-
-
27744506881
-
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
-
Lassman AB, Rossi MR, Raizer JJ, Abrey LE, Lieberman FS, Grefe CN, Lamborn K, Pao W, Shih AH, Kuhn JG, Wilson R, Nowak NJ, Cowell JK, DeAngelis LM, Wen P, Gilbert MR, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res. 2005; 11:7841-7850.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 7841-7850
-
-
Lassman, A.B.1
Rossi, M.R.2
Raizer, J.J.3
Abrey, L.E.4
Lieberman, F.S.5
Grefe, C.N.6
Lamborn, K.7
Pao, W.8
Shih, A.H.9
Kuhn, J.G.10
Wilson, R.11
Nowak, N.J.12
Cowell, J.K.13
DeAngelis, L.M.14
Wen, P.15
Gilbert, M.R.16
-
40
-
-
40749142429
-
Radiotherapy in lung adenocarcinoma with brain metastases: Effects of activating epidermal growth factor receptor mutations on clinical response
-
Gow CH, Chien CR, Chang YL, Chiu YH, Kuo SH, Shih JY, Chang YC, Yu CJ, Yang CH, Yang PC. Radiotherapy in lung adenocarcinoma with brain metastases: Effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res. 2008; 14:162-168.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 162-168
-
-
Gow, C.H.1
Chien, C.R.2
Chang, Y.L.3
Chiu, Y.H.4
Kuo, S.H.5
Shih, J.Y.6
Chang, Y.C.7
Yu, C.J.8
Yang, C.H.9
Yang, P.C.10
-
41
-
-
77956060394
-
High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer
-
Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol. 2010; 99:283-286.
-
(2010)
J Neurooncol
, vol.99
, pp. 283-286
-
-
Clarke, J.L.1
Pao, W.2
Wu, N.3
Miller, V.A.4
Lassman, A.B.5
-
42
-
-
84856304068
-
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant nonsmall cell lung cancer
-
Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, Clarke JL, Lassman AB. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant nonsmall cell lung cancer. Neuro Oncol. 2011; 13:1364-1369.
-
(2011)
Neuro Oncol
, vol.13
, pp. 1364-1369
-
-
Grommes, C.1
Oxnard, G.R.2
Kris, M.G.3
Miller, V.A.4
Pao, W.5
Holodny, A.I.6
Clarke, J.L.7
Lassman, A.B.8
-
43
-
-
84856235127
-
Outcome, quality of life and cognitive function of patients with brain metastases from nonsmall cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomid. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
-
Pesce GA, Klingbiel D, Ribi K, Zouhair A, von Moos R, Schlaeppi M, Caspar CB, Fischer N, Anchisi S, Peters S, Cathomas R, Bernhard J, Kotrubczik NM, D'Addario G, Pilop C, Weber DC, et al. Outcome, quality of life and cognitive function of patients with brain metastases from nonsmall cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). Eur J Cancer. 2012; 48:377-384.
-
(2012)
Eur J Cancer
, vol.48
, pp. 377-384
-
-
Pesce, G.A.1
Klingbiel, D.2
Ribi, K.3
Zouhair, A.4
von Moos, R.5
Schlaeppi, M.6
Caspar, C.B.7
Fischer, N.8
Anchisi, S.9
Peters, S.10
Cathomas, R.11
Bernhard, J.12
Kotrubczik, N.M.13
D'Addario, G.14
Pilop, C.15
Weber, D.C.16
-
44
-
-
10444237217
-
Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity
-
Chiu CH, Tsai CM, Chen YM, Chiang SC, Liou JL, Perng RP. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer. 2005; 47:129-138.
-
(2005)
Lung Cancer
, vol.47
, pp. 129-138
-
-
Chiu, C.H.1
Tsai, C.M.2
Chen, Y.M.3
Chiang, S.C.4
Liou, J.L.5
Perng, R.P.6
|